Related Experiment Videos
Clinical experience with percutaneous intra-aortic balloon pumping in cardiogenic shock complicating acute myocardial
Insights
Percutaneous intra-aortic balloon pumping (IABP) effectively treated cardiogenic shock and heart failure after myocardial infarction. This intervention improved hemodynamic parameters and patient outcomes, with a high success rate and manageable complications.
Area of Science:
- Cardiology
- Interventional Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock and medically refractory heart failure complicating acute myocardial infarction (CS/MRHF-AMI) have high mortality rates.
- Intra-aortic balloon pumping (IABP) is a mechanical circulatory support device used in managing acute cardiovascular conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of percutaneously inserted intra-aortic balloon pumping (IABP) in patients with CS/MRHF-AMI.
- To assess the impact of IABP on hemodynamic parameters and clinical outcomes in this patient population.
Main Methods:
- A prospective study involving 22 patients (37-78 years old) with CS/MRHF-AMI who underwent percutaneous IABP insertion between July 1984 and December 1987.
- Hemodynamic parameters including cardiac index, systolic arterial pressure, heart rate, pulmonary artery wedge pressure, and urine output were monitored before and during IABP therapy.
Main Results:
- IABP was successful in 21 out of 22 patients, with only one failure due to severe iliofemoral atherosclerosis.
- In 17 patients with cardiogenic shock, IABP reversed shock syndrome within 10-48 hours, significantly improving cardiac index, blood pressure, and urine output while decreasing heart rate and pulmonary artery wedge pressure.
- Twelve patients were weaned from IABP, and 8 were discharged, with a mean follow-up of 23 months. Four patients underwent surgical reperfusion or infarctectomy.
- The main complication was leg ischemia in 7 patients, requiring intervention in 3 cases.
Conclusions:
- Percutaneous IABP is a highly effective treatment for CS/MRHF-AMI, leading to significant hemodynamic improvement and favorable clinical outcomes.
- IABP can be safely implemented with a low failure rate, although leg ischemia is a notable complication that requires monitoring and management.
- This study supports the use of IABP as a critical intervention for patients experiencing acute myocardial infarction complicated by cardiogenic shock or refractory heart failure.
Abstract:
From July 1984 to December 1987, intra-aortic balloon pumping (IABP) was attempted percutaneously to 22 patients at the ages of 37-78 with cardiogenic shock or medically refractory heart failure complicating acute myocardial infarction (CS/MRHF-AMI). There was only one failure because of severe bilateral iliofemoral atherosclerosis. Of the 21 patients undergoing IABP, 17 were in cardiogenic shock and 13 of them showed reversal of shock syndrome after 10 to 48 hours of IABP. Cardiac index increased from 1.91 +/- 0.43 to 2.45 +/- 0.43 L/min/M2 (P less than 0.005), spontaneous systolic arterial pressure rose from 79 +/- 10 to 114 +/- 19 mmHg (P = 0.0001), heart rate dropped from 111 +/- 26 to 85 +/- 13 beats/min (P = 0.0001), pulmonary artery wedge pressure decreased from 29 +/- 5 to 16 +/- 3 mmHg (P = 0.0001), and urine output increased from 7 +/- 10 to 79 +/- 22 ml/h (P = 0.0001). Twelve patients, including 4 shock-free, were subsequently weaned from balloon assistance. Of these patients, 8 (5 shock and 3 nonshock) were discharged from the hospital and followed-up for a mean period of 23 months (4 to 38 months). Of the surviving patients, 4 underwent surgical reperfusion and/or infarctectomy during balloon support (n = 1) or after weaning from IABP (n = 3). All of the 10 patients who underwent coronary angiogram were found a severe left anterior descending artery lesion. The main complication was leg ischemia, which was observed in 7 patients: 3 needed removal or replacement of balloon catheter and one required surgical removal of the thrombus.(ABSTRACT TRUNCATED AT 250 WORDS)